SLC10A2, solute carrier family 10 member 2, 6555

N. diseases: 66; N. variants: 9
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2750087
Disease: Bile Acid Malabsorption, Primary
Bile Acid Malabsorption, Primary 		0.710 CausalMutation disease CLINVAR
CUI: C2750087
Disease: Bile Acid Malabsorption, Primary
Bile Acid Malabsorption, Primary 		0.710 Biomarker disease CTD_human
CUI: C0015544
Disease: Failure to Thrive
Failure to Thrive 		0.100 Biomarker disease HPO
CUI: C0038238
Disease: Steatorrhea
Steatorrhea 		0.100 Biomarker phenotype HPO
CUI: C0401151
Disease: Chronic diarrhea
Chronic diarrhea 		0.100 Biomarker disease HPO
CUI: C0456070
Disease: Growth delay
Growth delay 		0.100 Biomarker phenotype HPO
CUI: C1861403
Disease: Variable expressivity
Variable expressivity 		0.100 Biomarker phenotype HPO
CUI: C0011991
Disease: Diarrhea
Diarrhea 		0.030 Biomarker phenotype BEFREE Diarrhea in PFIC1/BRIC1 patients has a secretory origin to which SLC10A2 deficiency may contribute. 25239307 2014
CUI: C2747802
Disease: Bile acid malabsorption
Bile acid malabsorption 		0.040 GeneticVariation disease BEFREE ASBT gene polymorphisms were detected in 5 of the 13 adult IBAM patients. 11589382 2001
CUI: C0010346
Disease: Crohn Disease
Crohn Disease 		0.020 AlteredExpression disease BEFREE ASBT expression in ileal biopsies from patients with Crohn's disease and from healthy subjects was quantified by western blot. 14684580 2004
CUI: C4082937
Disease: Necrotizing enterocolitis in fetus OR newborn
Necrotizing enterocolitis in fetus OR newborn 		0.020 AlteredExpression disease BEFREE Apical sodium-dependent bile acid transporter upregulation is associated with necrotizing enterocolitis. 20616306 2010
CUI: C0520459
Disease: Necrotizing Enterocolitis
Necrotizing Enterocolitis 		0.010 AlteredExpression disease BEFREE Apical sodium-dependent bile acid transporter upregulation is associated with necrotizing enterocolitis. 20616306 2010
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.020 Biomarker disease BEFREE Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids. 26210740 2015
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.020 Biomarker disease BEFREE Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids. 26210740 2015
CUI: C0011991
Disease: Diarrhea
Diarrhea 		0.030 AlteredExpression phenotype BEFREE A decrease in ASBT function and expression has been implicated in diarrhea associated with intestinal inflammation. 22403793 2012
CUI: C0400966
Disease: Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease 		0.030 Biomarker disease BEFREE Activation or modulation of bile acid receptors, such as the farnesoid X receptor and TGR5, and transporters, such as the ileal apical sodium-dependent bile acid transporter, appear to affect both insulin sensitivity and NAFLD/NASH pathogenesis at multiple levels, and these approaches hold promise as novel therapies. 27358174 2017
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease 		0.030 Biomarker disease BEFREE Activation or modulation of bile acid receptors, such as the farnesoid X receptor and TGR5, and transporters, such as the ileal apical sodium-dependent bile acid transporter, appear to affect both insulin sensitivity and NAFLD/NASH pathogenesis at multiple levels, and these approaches hold promise as novel therapies. 27358174 2017
CUI: C0020557
Disease: Hypertriglyceridemia
Hypertriglyceridemia 		0.020 AlteredExpression phenotype BEFREE And bioinformatics studies discovered that the expression of slc10a2 was increased in high-grade hypertriglyceridemia patients. 29642873 2018
CUI: C0021831
Disease: Intestinal Diseases
Intestinal Diseases 		0.010 Biomarker group LHGDN Bile acid transporters in health and disease. 18668439 2008
CUI: C0020480
Disease: Hyperlipoproteinemia Type IV
Hyperlipoproteinemia Type IV 		0.020 AlteredExpression disease BEFREE Commensurate with these mRNA levels, the mean ASBT protein level in the control group was 126.2 +/- 22.6 versus 58.8 +/- 13.8 in hypertriglyceridemics (P = 0.02) and 61.8 +/- 15.2 in the FHT patients (P = 0.05). 10974045 2000
CUI: C0004763
Disease: Barrett Esophagus
Barrett Esophagus 		0.030 AlteredExpression disease BEFREE Correlation with ASBT expression was found for CDX1, CDX2, and HNF-1α in BE biopsies. 22016432 2012
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus 		0.010 Biomarker group BEFREE Current studies were designed to investigate the modulation of ASBT function and expression in streptozotocin (STZ)-induced diabetes mellitus in rats and to examine the effect of insulin on rat ASBT promoter by insulin. 20651004 2010
CUI: C0009241
Disease: Cognition Disorders
Cognition Disorders 		0.300 Biomarker group CTD_human Diabetic cognitive dysfunction is associated with increased bile acids in liver and activation of bile acid signaling in intestine. 29382564 2018
CUI: C0342257
Disease: Complications of Diabetes Mellitus
Complications of Diabetes Mellitus 		0.300 Biomarker group CTD_human Diabetic cognitive dysfunction is associated with increased bile acids in liver and activation of bile acid signaling in intestine. 29382564 2018
CUI: C4551898
Disease: Cholestasis, progressive familial intrahepatic 1
Cholestasis, progressive familial intrahepatic 1 		0.020 Biomarker disease BEFREE Diarrhea in PFIC1/BRIC1 patients has a secretory origin to which SLC10A2 deficiency may contribute. 25239307 2014